Third trimester amniotic fluid (AF)-derived human mesenchymal stem cells (MSCs) can be greatly expanded in vitro and induced to differentiate into multiple mesenchymal cell types. This study aimed to investigate the biological characteristics of MSCs from third trimester AF as a new source of therapeutic stem cells. Forty third trimester AF samples were obtained from healthy women who underwent elective caesarean section for breech presentation. A simple culture protocol for MSCs was used. A cell growth curve was drawn, and cell surface antigens and cytokines were analysed by immunofluorescent staining, reverse transcription-polymerase chain reaction and flow cytometry. MSCs from third-trimester AF were successfully isolated, cultured and enriched. MSCs expanded extensively without feeders, they were not tumourigenic and were induced to differentiate into osteocytes. Surface antigens were analysed and found to express the pluripotency marker Oct-4. Considering the great feasibility of biomedical engineering using MSCs, third trimester AF may provide a rich source for investigation of human MSCs.
Introduction
Amniotic fluid (AF) is known to contain multiple cell types derived from the developing fetus and AF stem cells comprise about 1% of the cells found in AF, representing the three primary embryonic lineages of the mesoderm, ectoderm and definitive endoderm. 1 Embryonic stem (ES) cells are distinguished from adult stem cells by their potential for selfrenewal and multi-lineage differentiation. 2, 3 The basis of most current ethical concerns with ES cells arises from the need to derive the cell type from developing blastocysts because it interrupts normal development of an embryo, which might have produced a human life. Derivation of ES-like stem cells from AF, however, would not be expected to raise the same objections. So far, samples of AF for research work have focused on amniocentesis samples from the second trimester, but the quantity of samples is limited and there is a known risk of miscarriage at this stage of pregnancy.
In hospitals, AF is discarded after a birth so the use of term AF as a stem cell source would obviate most, if not all, ethical, religious and political concerns. If it could be definitively demonstrated that each Q You, X Tong, Y Guan et al. Characteristics of third trimester amniotic fluid stem cells individual that is born could have 'spare parts' derived from AF, these stem cells would be a unique recycling biotechnology. In theory, AF stem cells could be isolated from almost every newborn baby. In China, more than 16 million live births occur per year. 4 Once technology is established to develop pluripotent stem cell lines from each AF sample, it would be easier to complete banks with all major histocompatibility complex immunotypes for further clinical applications. These potential advantages led to the present investigation of the possible stem cell nature of mesenchymal stem cells (MSCs) from third trimester AF.
Materials and methods

MSCS ISOLATION AND CULTURE
Third trimester AF samples were harvested during 40 deliveries at a mean gestational age of 34 +2 (SD ± 1) weeks involving women who underwent elective caesarean section for breech presentation. The AF samples were collected by puncture through the membranes after opening the uterine wall during caesarean section. Written and verbal informed consent was obtained from the subjects and the study protocol was approved by the Ethics Committee of Harbin Medical University, China.
Cells were isolated from AF samples no more than 4 h prior to use in the experiments. The AF samples were centrifuged at 1100 rpm (220 g) for 5 min and all the cells isolated from a sample were plated into six 35-mm Petri dishes with a glass coverslip containing L-glucose Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA, USA) supplemented with 100 U/ml penicillin, 0.1 mg/ml streptomycin (Invitrogen), 10 ng/ml basic fibroblast growth factor (PeproTech, Rocky Hill, NJ, USA), 10 ng/ml epidermal growth factor (Peprotech) and 20% fetal bovine serum (FBS; Invitrogen). The cells were incubated at 37°C with 5% humidified CO 2 for MSCs culture. At day 7 after the initiation of culture, the medium was replaced with fresh medium and non-adhering cells were removed; the medium was subsequently replaced twice weekly.
When the cells reached about 70% confluence (day 12), they were treated with 0.25% trypsin (Invitrogen) and 1 mM ethylenediaminetetra-acetic acid (EDTA; Invitrogen) for 3 min. The released MSCs were collected and replated 1:3 under the same culture conditions. The cell concentration was 4 × 10 4 cells/ml and they were labelled as cell passage 1.
Cells were examined by optical and electron microscopy.
POPULATION DOUBLING
The MSCs at passages 2, 5 and 8 were trypsinized and inoculated into 24-well Petri dishes, 0.5 ml/well (cell concentration 1 × 10 4 /ml). The cells were incubated at 37°C with 5% humidified CO 2 and the medium was subsequently replaced twice a week. The MSCs took 48 h to adhere to the Petri dishes and, after this period, three wells of cells were taken every 24 h and their mean cell number was recorded as the population cell number for that day. The time for the MSCs to double in population (TD) were calculated using the formula:
, where N 0 is the inoculum cell number and N t is the cell harvest number at time t.
FLOW CYTOMETRY ANALYSIS
The specific surface antigens of MSCs at passages 3 -8 were characterized by flow cytometry analyses. The cells in culture were trypsinized and stained with phycoerythrin (PE)-conjugated mouse monoclonal antibodies against CD29, CD31, CD45, CD61, CD73, CD90 and CD105 (BD Q You, X Tong, Y Guan et al.
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Biosciences PharMingen, San Jose, CA, USA). Thereafter, the cells were analysed using a flow cytometer (Becton, Dickinson and Co, San Jose, CA, USA).
IMMUNOFLUORESCENT STAINING
A total of 1 × 10 4 AF-MSCs at passages 3 -10 were plated per well and cultured in a 24-well Petri dish with a glass coverslip containing the AF-MSCs culture medium described above, overnight at 37°C in a 5% humidified CO 2 incubator. The next day the cells were washed with 10 mM phosphate buffered saline (PBS), pH 7.4, and fixed for 30 min in 2% paraformaldehyde (Sigma-Aldrich, St Louis, MO, USA) at 4°C. The cells were permeabilized in 0.2% Triton-X (Sigma-Aldrich) for 30 min at room temperature and incubated for a further 20 min in blocking buffer (10% FBS in PBS). The cells were then stained with primary antibody, 1 µg/ml Oct-3/4 mouse anti-human monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) in PBS for 1 h. As the secondary antibody, 0.5 µg/ml fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse (Santa Cruz Biotechnology) was used in PBS for 45 min.
RNA EXTRACTION AND RT-PCR
Total RNA was extracted from the cultured cells using TRI Reagent ® (Invitrogen) according to the manufacturer's instructions. Reverse transcription-polymerase chain reaction (RT-PCR) was performed using the One-Step RT-PCR kit (Invitrogen) using specific DNA primers as follows: Oct-4 (247 base pairs [bp]) sense, 5′-CGTGAAGCTGG AGAAGGAGAAGCTG-3′ and antisense, 5′-C AAGGGCCGCAGCTTACACATGTTC-3′; and β-actin (396 bp) sense, 5′-TGGCACCAC ACCTTCTACAATGAGC-3′ and antisense, 5′-GCACAGCTTCTCCTTAATGTCACGC-3′. The RT-PCR was performed initially at 30°C for 10 min, 42°C for 30 min, 99°C for 5 min and 5°C for 5 min for reverse transcription, then followed by 30 cycles, with each cycle consisting of denaturation at 94°C for 30 s, annealing at 55°C for 30 s, elongation at 72°C for 1 min and final extension at 72°C for 10 min. The amplified DNA fragments were visualized through 1% agarose gel electrophoresis, stained and photographed under UV light. NTERA-2 cl.D1 cells (ATCC CRL-1973), a pluripotent human testicular embryonic carcinoma cell line, and MRC-5 cells (human diploid lung fibroblast, ATCC CCL-171) were used as positive and negative controls for Oct-4 RT-PCR expression analysis, respectively. All cells lines were obtained from the Chinese Academy of Agricultural Sciences, Beijing, China. The PCR products of β-actin served as an internal control.
TUMOUR FORMATION
The rear leg muscles of 46 female nude BALB/c mice of age 4 weeks were injected with MSCs (3 -8 × 10 6 cells/animal). The mice were housed in a specific pathogen free (SPF) animal area at the Department of Laboratory Animal Resources (LAR) of Harbin Medical University. All staff were trained in SPF animal care and use, and implemented and monitored compliance with SPF standards of care and use for SPF-designated mice. The mice were sacrificed 3 months after injection and the injected muscles were subjected to histological examination.
OSTEOGENIC DIFFERENTIATION POTENTIAL ASSAY FOR MSCS
The MSCs were cultured to about 70% confluence and shifted to osteogenic medium with replacement of the medium twice a week. The osteogenic medium was L-DMEMsupplemented with 10% FBS (Invitrogen), 1% antibiotics, 50 µg/ml ascorbate-2-phosphate (Sigma) and 100 mM β-glycerophosphate Q You, X Tong, Y Guan et al. Characteristics of third trimester amniotic fluid stem cells (Sigma) . Osteogenic differentiation was evaluated after 2 weeks by measuring expression of the marker gene, osteopontin (OPN) using RT-PCR as previously described. 5
Results
MSCS CULTURE AND EXPANSION
Colonies of MSCs began to appear in the culture flasks 9 days after removing the nonadhering cells from the primary AF cell culture and, after 2 weeks' culture, the cells had grown to 70% density and at this stage they were trypsinized and re-seeded into 3.5 cm flasks. The subsequent passages were carried on in these 3.5-cm flasks under the same conditions at a split ratio of 1:2 -1:4. Currently, the 20thpassage culture has been completed in our laboratory. Optical and electron microscopy examination of MSCs on day 9 showed the MSCs to be fusiform and fibroblast-like (Fig. 1) .
MSCS GROWTH CURVE
The MSCs growth curve had the following characteristics: (i) in the first 2 days after inoculation the cells adhered to the Petri dish; (ii) from day 3 the cells entered the logarithmic growth stage; (iii) peak growth was on day 7; (iv) MSCs at passage 8 grew slower than those at passages 2 and 5; and (v) the doubling time of the MSCs was 30.5 h (Fig. 2 ). 
FLOW CYTOMETRY ANALYSIS
The expression of surface antigens carried out by flow cytometry using mouse monoclonal antibodies are shown in Fig. 3 . The MSCs were positive for CD29, CD73, CD90 and CD105 and negative for CD31, CD45 and CD61.
MSCS OCT-4 EXPRESSION
Oct-4 is a key marker expressed in ES cells and is responsible for the maintenance of pluripotency of mammalian stem cells in vivo and in vitro. 6, 7 Nuclear immunofluorescent staining of cultured MSCs showed that they were positive for Oct-4, and this may indicate increased pluripotency (Fig. 4) .
Analysis by RT-PCR showed that Oct-4 mRNA expression was detectable in the cultured MSCs (Fig. 5 ).
TUMOUR FORMATION
Three months after injection of MSCs into the rear leg muscles of 4-week-old female nude BALB/c mice no tumours were observed on histological examination.
OSTEOGENIC DIFFERENTIATION POTENTIAL OF MSCS
When MSCs at passage 5 were cultured in osteogenic medium for 2 weeks, the MSCs were observed to differentiate into osteoblasts (Fig. 6A) , and the results of RT- 
Discussion
Normal MSCs from 40 third trimester AF samples were successfully isolated and expanded in the present study, thereby demonstrating that multi-potent MSCs are present in third trimester human AF. These results are consistent with recent reports 8, 9 that MSCs from AF show multilineage potential for differentiation.
There are several advantages to collecting third trimester AF during caesarean sections compared with collecting AF by amniocentesis during the second trimester: (i) it is possible to collect a larger volume of AF during a caesarean section than by amniocentesis; (ii) the approach does not increase the possibility of uterine contamination and is less invasive than collection during the second trimester; and (iii) third trimester AF is much easier to collect and so is a richer source of MSCs than second trimester AF.
Worldwide there are now more than 1000 stem cell-based therapies in early human trials. Until now, the vast majority of these therapies have been conducted using stem cells from patients' own bone marrow or derived from cord blood banks. Some companies also soon intend to begin the first human trials involving ES cells; ES cell lines are the in vitro manifestation of cells of the inner cell mass 10 derived from blastocysts. Apart from ethical and moral concerns, ES cells can be differentiated into most of the cell lineages of a living organism, but the tumour-forming potential of ES cells has led to a significant problem in realizing therapeutic applications; over the last few years, numerous papers have shown tumour formation in animals treated with differentiated ES cell derivatives. 11 -13 AF MSCs can solve this problem. MSCs from AF also express embryonic cell lineage markers after in vitro culture and share the differentiation capabilities of human ES cells. 14 One of the major advantages of MSCs derived from AF is making autologous transplantation possible; the recipient and the donor can be the same person, which will be very important for the replacement of damaged, aged or diseased tissues with new cells. In the future, banking AF-derived MSCs may provide a rich and convenient source for both autologous therapy and matching of histocompatible donor cells with recipients.
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